Host: Gerald Watts, MD, PhD <br>


  
    <p>There is a high unmet need for patients with persistent chylomicronemia. Plozasiran (ARO-APOC3) is an investigational drug that is being evaluated for these patients. Professor Gerald Watts shares the outcomes of the PALISADE trial, in which the efficacy and safety of plozasiran was examined in patients with familial chylomicronemia syndrome. </p>

Host: Gerald Watts, MD, PhD There is a high unmet need for patients with persistent chylomicronemia. Plozasiran (ARO-APOC3) is an investigational drug that is being evaluated for these patients. Professor Gerald Watts shares the outcomes of the PALISADE trial, in which the efficacy and safety of plozasiran was examined in patients with familial chylomicronemia syndrome.

Share Phase 3 study results of plozasiran in patients with FCS

Sign up to save your podcasts

Phase 3 study results of plozasiran in patients with FCS

Phase 3 study results of plozasiran in patients with FCS